Cytomegalovirus retinitis after one decade of HAART

International Ophthalmology Clinics

Volumn 47, Issue 2, 2007, Pages 155-164

  Sobrin, Lucia ^a   Stephen Foster, C ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CORTICOSTEROID; FOSCARNET; GANCICLOVIR; PROBENECID; VALGANCICLOVIR;

BLOOD TOXICITY; CLINICAL FEATURE; CREATININE CLEARANCE; CYTOMEGALOVIRUS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ELECTROLYTE DISTURBANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRAOCULAR PRESSURE; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; RETINITIS; REVIEW; SIDE EFFECT; UVEITIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOMEGALOVIRUS RETINITIS; HUMANS; INCIDENCE;

EID: 34248188148     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e3180377814     Document Type: Review

References (38)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:851-860.
2. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72:2059-2064.
3. Rao NA, Zhang J, Ishimoto S. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans Am Ophthalmol Soc. 1998;96:111-123.
4. Scholz M, Doerr HW, Cinatl J. Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol. 2003;11:171-178.
5. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575-582.
6. McCann JD, Margolis TP, Wong MG, et al. A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis. Am J Ophthalmol. 1995;120:219-226.
7. Knox CM, Chandler D, Short GA, et al. Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis; use in diagnostic dilemmas. Ophthalmology. 1998;105:37-45.
8. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial 4. Visual outcomes. Ophthalmology. 1994;101:1250-1261.
9. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-1126.
10. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant; Roche Ganciclovir Study. N Engl J Med. 1999;340:1063-1070.
11. Studies of the Ocular Complications of AIDS Research Group in Collaboration with AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS; The Cytomegalovirus Retreatment Trial. Arch Ophthalmol. 1996;114:23-33.
12. Hatton MP, Duker JS, Reichel E, et al. Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant. Retina. 1998;18:50-55.
13. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant; The Ganciclovir Implant Study Group. N Engl J Med. 1997;337:83-90.
14. Roth DB, Feuer WJ, Blenke AJ, et al. Treatment of recurrent cytomegalovirus retinitis with the ganciclovir implant. Am J Ophthalmol. 1999;127:276-282.
15. Díaz-Llopis M, Chipont E, Sanchez S, et al. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;114:742-747.
16. Young S, Morlet N, Besen G, et al. High- dose (2000-μg) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105:1404-1410.
17. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol. 1997;115:733-737.
18. Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998;177:1182-1187.
19. Studies of Ocular Complication of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. J Infect Dis. 1997;176:50-58.
20. Jabs DA, Enger C, Dunn JP, et al., for the Cytomegalovirus Retinitis and Viral Resistance Study Group. Cytomegalovirus retinitis and viral resistance: 4. Ganciclovir resistance. J Infect Dis. 1998;177:770-773.
21. Jabs DA, Martin BK, Forman MS, et al., for the Cytomegalovirus Retinitis and Viral Resistance Study Group. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;135:26-34.
22. Jabs DA, Enger C, Forman M, et al., for the Cytomegalovirus Retinitis and Viral Resistance Study Group. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agent Chemother. 1998;42:2240-2244.
23. Weinberg A, Jabs A, Chou S, et al., for the Cytomegalovirus Retinitis and Viral Resistance Study Group and the Adult AIDS Clinical Trials Group Cytomegalovirus Laboratories. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2003;187:777-784.
24. Jabs DA, Martin BK, Forman MS, et al., for the Cytomegalovirus Retinitis and Viral Resistance Study Group. Longitudinal observations on mutations conferring resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: the cytomegalovirus and viral resistance study group report number 8. Am J Ophthalmol. 2001;132:700-710.
25. Jabs DA, Martin BK, Forman MS, et al., for the Cytomegalovirus Retinitis and Viral Resistance Research Group. Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitis. J Infect Dis. 2005;192:640-649.
26. Davis JL, Serfass MS, Lai MY, et al. Silicone oil in repair of retinal detachments caused by necrotizing retinitis in HIV infection. Arch Ophthalmol. 1995;113:1401-1409.
27. Dugel PU, Liggett PI, Lee MB, et al. Repair of retinal detachment caused by cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1991;112:235-242.
28. Morrison VL, Labree LD, Azen SP, et al. Results of silicone oil removal in patients with cytomegalovirus retinitis related retinal detachments. Am J Ophthalmol. 2005;140:786-793.
29. Jabs DA, Van Natta ML, Thorne JE, et al. Studies of Ocular Complications of AIDS Research Group. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004;111:2224-2231.
30. Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003;121:466-476.
31. Jabs DA, Van Natta ML, Thorne JE, et al. Studies of Ocular Complications of AIDS Research Group. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004;111:2232-2239.
32. Kempen JH, Jabs DA, Wilson LA, et al. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Am J Ophthalmol. 2005;139:1028-1034.
33. Kempen JH, Jabs DA, Wilson LA, et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis. 2003;37:1365-1373.
34. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis; a new syndrome. Arch Ophthalmol. 1998;116:169-175.
35. Zegans ME,Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1998;125:292-300.
36. Wohl DA, Kendall MA, Owens S, et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005;6:136-146.
37. Song M-K, Azen S, Buley A, et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol. 2003;136:696-702.
38. Holland GN. Immune recovery uveitis. Ocular Immunol Inflamm. 1999;7:215-221.